Old Web
English
Sign In
Acemap
>
authorDetail
>
Ryan Demasi
Ryan Demasi
AbbVie
Rheumatoid arthritis
Adalimumab
Internal medicine
Medicine
Population
2
Papers
4
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis.
2020
Annals of the Rheumatic Diseases
Roy Fleischmann
Ricardo Blanco
Stephen Hall
Glen Thomson
Filip Van den Bosch
Cristiano A. F. Zerbini
Louis Bessette
Jeffrey V. Enejosa
Yihan Li
Y. Song
Ryan Demasi
In-Ho Song
Show All
Source
Cite
Save
Citations (2)
OP0029 SWITCHING BETWEEN THE JAK1-SELECTIVE INHIBITOR-UPADACITINIB AND ADALIMUMAB FOLLOWING INITIAL NON-RESPONSE: CLINICAL AND FUNCTIONAL OUTCOMES AMONG RHEUMATOID ARTHRITIS PATIENTS
2019
Annals of the Rheumatic Diseases
Mark C. Genovese
Roy Fleischmann
Ricardo Blanco
Stephen Hall
Glen Thomson
Filip Van den Bosch
Cristiano A. F. Zerbini
Jose Jeffrey Enejosa
LI Yihan
Ryan Demasi
In-Ho Song
Show All
Source
Cite
Save
Citations (2)
1